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Abstract
Current evidence suggests dementia and pathology in Alzheimer’s Disease (AD) are both dependent and independent of
amyloid processing and can be induced by multiple ‘hits’ on vital neuronal functions. Type 2 diabetes (T2D) poses the
most important risk factor for developing AD after ageing and dysfunctional IR/PI3K/Akt signalling is a major contributor
in both diseases. We developed a model of T2D, coupling subdiabetogenic doses of streptozotocin (STZ) with a human
junk food (HJF) diet to more closely mimic the human condition. Over 35 weeks, this induced classic signs of T2D
(hyperglycemia and insulin dysfunction) and a modest, but stable deficit in spatial recognition memory, with very little
long-term modification of proteins in or associated with IR/PI3K/Akt signalling in CA1 of the hippocampus.
Intracerebroventricular infusion of soluble amyloid beta 42 (Aβ42) to mimic the early preclinical rise in Aβ alone induced
a more severe, but short-lasting deficits in memory and deregulation of proteins. Infusion of Aβ on the T2D phenotype
exacerbated and prolonged the memory deficits over approximately 4 months, and induced more severe aberrant regula-
tion of proteins associated with autophagy, inflammation and glucose uptake from the periphery. A mild form of envi-
ronmental enrichment transiently rescued memory deficits and could reverse the regulation of some, but not all protein
changes. Together, these data identify mechanisms by which T2D could create a modest dysfunctional neuronal milieu via
multiple and parallel inputs that permits the development of pathological events identified in AD and memory deficits
when Aβ levels are transiently effective in the brain.
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Introduction
Until more recently, much of the research into how pathology
in Alzheimer’s disease (AD) induces dementia has focussed
on the amyloid plaque, to the relative neglect of non-amyloid
specific pathologies associated with the disease. However, the
past decade has witnessed a paradigm shift away from the
hard core amyloid plaque as the major pathological mecha-
nism inducing the disease and ensuing dementia to the role of
soluble, toxic species of preaggregated amyloid and non-
specific pathologies [1, 2]. The main evidence supporting this
is treatments in clinical trials that remove plaques do not result
in improvement or slowing of the dementia [3], and imaging
studies suggesting amyloid load is an age-related phenome-
non that does not necessarily lead to dementia [4, 5]. Both
epidemiological and experimental evidence have identified a
number of dysfunctional/pathological events in AD, that are
not specific to AD, that include dysfunction in energy
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regulation, supply of nutrients, oxidative/ER stress, inflamma-
tion, mitogenic abnormalities, synaptic failure, autophagy and
disruption of the blood brain barrier and neurovasculature
[6–14].
A key question is whether these dysfunctions are directly
linked with the classic AD pathology in terms of being a cause
or consequence of amyloid pathology, or whether they are
independent pathologies occurring in parallel with amyloid
pathology. Whether causal or independent, it suggests that
these dysfunctional events may constitute a multiple ‘attack’
on the brain, and the question becomes how they are induced.
Many of these dysfunctional events are associatedwith known
metabolic risk factors for developing AD that develop slowly
over time.
Ageing is the major risk factor for developing AD, howev-
er, following that type 2 diabetes (T2D), poses the greatest
known risk; epidemiological studies show a large percentage
of people with T2D go on to develop AD [15] and diabetic
patients show similar cognitive deficits to those at early stage
AD [16]. Adult T2D is characterised by peripheral hypergly-
cemia, dysfunctional insulin signalling and chronic low-grade
inflammation and begins to manifest the symptoms in mid
life, a time that coincides with the early increase in soluble
Aβ40/42 in the brains of human subjects predicted to develop
AD [17]. However, as AD, T2D is a multifactorial disease and
subject to risk factors, most notably obesity [18] that is highly
linked with the development of hyperinsulinemia [19] and
develops slowly over time.
Both diseases share common pathologies albeit they have
been identified in the periphery with T2D and in the brain with
AD. These include an increase in inflammation, dysregulation
of glucose and insulin signalling and these are mediated, at
least in part, via IR/PI3K/Akt signalling [20, 21]. Although it
has been suggested that T2D pathologies can promote early
neurodegenerative processes, the mechanisms by which this
occurs are complex and poorly understood [see 22]. One pos-
sibility is that peripheral hyperinsulinemia and hyperglycemia
associated with T2D impairs the uptake of insulin and glucose
across the blood brain barrier (BBB) [23] to induce dysfunc-
tional insulin signalling in the brain, and chronic low-grade
inflammation may impact the BBB to allow inflammatory
molecules to pass through.
To date, numerous studies have shown links between pa-
thologies associated T2D and AD using different approaches.
For example, dysfunction regulation of the IR/PI3K/Akt sig-
nalling pathway has been shown in postmortem brains of pa-
tients with AD [24–26]; development of AD pathology ob-
served in rodent models of T2D [27]; acceleration of AD
pathology in transgenic AD mice fed high fat and/or high
sucrose diets [28–31]; antidiabetic treatment in humans with
AD, and murine models of the disease show some improve-
ment in cognition and memory and afford a certain level of
protection against inflammation, apoptosis and synaptic
failure in the brain [32, 33]. Finally, studies have recapitulated
dysfunction in glucose metabolism, IR/PI3K/Akt signalling
and the induction of inflammation and regulation of Tau and
and Aβ processing in the brain following icv injection of the
diabetogenic toxin, Streptozotocin (STZ) [see 34, 35]. Despite
the number of studies and different approaches, they have
produced mixed results that may be inherently linked with
variables such as the type of model used, the duration of the
experiments, type of diet, etc. Therefore, it is difficult to have a
clear idea of how these dysfunctions link T2D to AD.
The aim of our experiments is therefore dual fold. Firstly, it
is to determine whether a T2D profile might exacerbate dys-
functional mechanisms in CA1 of the hippocampus induced
by early increases in soluble amyloid associated with preclin-
ical stages of AD. To this end, we focussed on proteins in and
associated with IR/PI3K/Akt signalling that contribute to de-
regulation of functions such as apoptosis, autophagy, inflam-
mation, glucose uptake and the promotion of amyloid and tau
processing [20, 21, 36]. Secondly. in an attempt to more close-
ly mimic human T2D, we modified an established model of
T2D that normally couples subdiabetogenic doses of
Streptozotocin (STZ) with a calibrated high diet [37, 38] by
coupling STZ injections with a human junk food (HJF) diet. In
addition, we conducted longitudinal studies to determine the
evolution of dysfunction induced by different treatments.
Finally, as a functional readout, we repeatedly tested spatial
recognition memory and subsequently the potential beneficial
effect of environment enrichment (EE) has been shown to
have general positive effects on hippocampal dependent mem-
ory including spatial and recognition memory and some forms
of neuronal plasticity and mitigates deficits in rodent models
of pathology [39, 40].
Material and Methods
Animals
Male Sprague Dawley rats (n = 100), weighing approxi-
mately 300 g, were purchased from Charles River
Laboratories, France. The animals were housed in standard
cages (2 rats/cage) and maintained in a temperature and
humidity controlled colony room with 12/12-h light dark
cycle with fresh water ad libitum and normal laboratory
pellets (A04, SAFE, France) until the start the feeding pro-
tocol. All efforts were made to minimise the animal num-
bers and suffering throughout the experimental procedure.
Experiments were conducted according to the European
Communities Council Directive of 24 November 1986
(86/609/EEC), EU Directive 2010/63/EU, and the French
National Committee (87/848), and approval from the local
ethics committee (n°59).
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General Protocol and Experimental Groups
We conducted longitudinal studies over 9–10 months, where
rats were first started on a feeding regime of human junk food
(HJF) and then 7 weeks later, injected twice with
subdiabetogenic doses of Streptozotocin (STZ), 1 week apart.
At week 20, some of the rats were implanted with osmotic
minipumps containing soluble Aβ42 and the experiment was
continued for another 15 weeks. Throughout the experimental
period, regular glucose tolerance tests (GTTs) and spatial rec-
ognition memory tests were conducted (see timeline, Fig. 1).
In western blotting, we also used brains from naïve rats for
comparison with the control group.
Feeding Protocol
After 2 weeks’ of adaptation to laboratory conditions, rats were
randomly divided into two basic feeding regimes; those main-
tained on the calibrated laboratory diet (LD) at the recommend-
ed dose tomaintain normal health and growth; or human ‘junk’
food (HJF; see Online Resource 1) that was high in calories,
sugar and fat. Moreover, these foods contained chemical com-
ponents used as stabilisers, emulsifiers, colourants, etc. Awide
range of food products was offered to rats at the start of the
experiment to determine their food preference and from a pool
of about 20 foodstuff; 8–10 were given per day in excess, such
that on a weekly basis, all rats ate the same foods in about the
same quantity. This feeding regime was continued throughout
the experimental period and body weight was recorded on a
weekly basis. Consumption of major nutritional components in
HJF was assessed each day over a 6-week period in the middle
of the experiment.
Streptozotocin (STZ) Injections
STZ (Sigma- Aldrich) was dissolved in citric acid (pH 6.0),
prepared as required and protected from light. Rats were
fasted the night prior to given 2 sub-diabetogenic doses
(30 mg/kg i.p.) 1 week apart approximately 7 weeks after
the start of the feeding regime.
Amyloid-Beta (Aβ) Preparation, Infusion and Surgical
Procedures
The Aβ42 peptide was specifically synthesised to be main-
tained in a soluble form, as reported elsewhere [41] and stored
as lyophilised aliquots (0.1mg) at − 80° until required. Prior to
use, the peptide was resuspended in HyPure Molecular biolo-
gy double distilled sterile water (Thermo; France), sonicated,
diluted to a nominal concentration of 100 μM in aCSF (pH =
7.4, Alzet protocol), and filtered through a membrane filter
(100 nm pore size, PVDF sterile, Millex, Millipore) to remove
the insoluble aggregates. The final concentration was made in
aCSF to 50 μM; the exact value was determined by a standard
BCA assay.
For the TEM experiments, 10 μl aliquots were placed on
formvar carbon 400-mesh copper grids (Electron Microscopy
Sciences, Washington, PA, USA) after 168 h of incubation at
37 °C. Grids were stained with 2% (w/v) uranyl acetate.
Specimens were studied with a Philips CM 10 transmission
electronmicroscope (FEI Company, Hillsboro, Oregon, USA)
operating at 100 kV. Images were taken by aMegaview II Soft
Imaging System at a magnification of × 46000 and analysed
with an AnalySis® 3.2 software package (Soft Imaging
System GmbH, Münster, German).
Approximately 20 weeks after the start of the feeding re-
gime, half of the rats in each group underwent surgery to im-
plant osmotic minipumps (Alzet, model 2004, USA) to infuse
Aβ42 intraventricularly (icv) over 7 days (0.5 μl/h). Rats were
deeply anaesthetised with Ketamine (1.5 ml/kg) and Domitor
(0.5 ml/kg). They were placed in a stereotaxic frame, the skull
exposed to allow a single hole to be drilled out to place a
cannula in the lateral ventricle (Bregma 1.3 mm; midline
1.8 mm; depth 3.0 mm from the brain surface). The cannula
was connected to osmotic minipump via flexible tubing and
fixed to the scalp with dental cement. The pump was then
inserted subcutaneously between the scapula and the scalp
incision was closed with surgical staples and swabbed with
topical antiseptic and rats had a 5-day course of antibiotics.
Glucose Tolerance Test (GTT)
At different time points during the experiment (see Fig. 1),
glucose tolerance tests were conducted. After overnight
fasting, blood from the tail vein (approximately 4 μl each
time) was sampled prior to (0 min) and 15, 30, 60 and
120 min following a bolus injection of glucose (i.p, 2 g/kg
body weight, Sigma- Aldrich,). Blood glucose levels (mg/dL)
were analysed using a glucometre (HemoCueR, Sweden).
Analyses were conducted on basal (0 min) glucose levels
and the area under curve (AUC) in response to the glucose
challenge in each rat using Analysis of Variance (ANOVA).
Blood Insulin Assay
At the end of the experiment after overnight fasting, whole
blood was collected immediately following sacrifice. Plasma
was separated by centrifugation (3500 rpm, 25 min, at 4 °C)
and stored at − 20 °C until analysis. Plasma insulin was mea-
sured using a Rat/Mouse Insulin ELISA Kit (Cat # EZRMI-
13K, Millipore, Germany) according to the manufacturer’s
protocol and analysed using spectrophotometry (Molecular
Device, France) at an absorbance level of 450 nm. Sample
insulin concentrations (ng/ml) were calculated based on stan-
dard insulin curves and ANOVA was used to analyse group
differences.
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Recognition Memory Task
Recognition memory was conducted in a circular open field
(diameter 90 cm, height 50 cm, painted black) in a room
containing multiple 3-dimensional cues. Before training, rats
were habituated to the open field (5 min/day, for 3 days).
Following habituation, rats were given a sample phase (3 ses-
sions of 4 min with a 4-min interval between sessions) where
they explored three different objects constructed out of
Lego™. At the first testing time point, we tested spatial rec-
ognition memory by changing the location of one of the ob-
jects during the sample phase following a 3 or 24 h delay, or
object recognition memory by replacing one of the familiar
objects for a novel one 24 h later. The test phase comprised a
single session of exploration (4min). Time spent exploring the
objects was recorded via a video tracking system
(ANYMAZE, Stoelting Co., USA). ANOVAwas used to an-
alyse the total time spent exploring objects during the sample
phase to determine whether differences in exploration would
indicate deficits in motor coordination or stress that may con-
tribute to cognitive performance. Percent time spent exploring
the novel location vs a mean of the two familiar locations was
calculated to determine 50% as chance level using the
Wilcoxon test and comparison between specific groups using
Student’s t test.
Environmental Enrichment
In a separate group of rats, we tested whether a mild form of
environmental enrichment (EE), developed in the laboratory
[42], would affect memory performance and protein regula-
tion in a subset of rats in the STZ-HJF and control groups
infused with Aβ or not. Groups of 4–5 rats were placed in a
large wooden box (length 100 cm, width 80 cm, height 60 cm)
containing junk objects for 3 h a day over 14 days. Objects
were changed and repositioned every day. Rats were tested on
the spatial recognition memory task after infusion of Aβ but
prior to EE, and then several times after EE. In these experi-
ments, we also tested memory with a 72-h delay after the
sample phase.
Brain Tissue Preparation for Biochemical Analyses
and Western Blotting Protocol
Rats were sacrificed by decapitation and CA1 of the hip-
pocampus was dissected for analyses of expression and
phosphorylation of proteins using immunowestern-blot-
ting. Dissected tissue was immediately frozen in liquid
nitrogen and kept at − 80 °C for later use. Proteins were
extracted from the frozen tissue in lysis buffer [43]; and
Complete Protease Inhibitor Cocktail and PhosSTOP
(Roche, France). Homogenised samples were incubated
on ice for 30 min and centrifuged at 15,000 rpm for
15 min at 4 °C; the supernatant was recovered and stored
at − 80 °C. Protein concentrations were calculated using
Bio-Rad protein assay (Bio-Rad, Germany) and samples
were diluted with lysis buffer to give equal protein con-
centration of 1 μg/μl.
We used a standard western blotting protocol where
20 μl of samples was denatured in 5 x Laemmli sample
buffer and boiled at 95 °C for 5 min before loading onto
gradient acrylamide gels (6–12%). Proteins were separated
using constant voltage (150 V) between 1.5 and 3 h and
then transferred onto a nitrocellulose membrane
(Amersham, GE Healthcare, Germany) by electro-blotting
at a constant voltage (100 V; 90 min). Membranes were
blocked with 5% non-fat dry milk (Bio-Rad, France) in
TBS-T (Euromedex, France) and incubated overnight in
primary antibodies at 4 °C with gentle shaking (see prima-
ry antibodies and dilution in Online Resource 2).
Membranes were washed 3 times (5 min) in TBS-T and
incubated in a horseradish peroxidase-conjugated anti-
mouse/ rabbit immunoglobulin IgG secondary antibody
(dilution 1:2000–1:10,000 in 5% BSA, Amersham, GE
Healthcare, France) for 1–1.5 h at room temperature.
Membranes were rinsed × 3 (5 min) in TBS-T and proteins
were reacted with Chemiluminescence ECL solution
(Amersham, GE healthcare, France), exposed to film (op-
timal exposure time for each antibody was maintained) and
developed by hand. Membranes were subsequently washed
and stripped (Re-blot plus; Millipore, Germany) and re-
Fig. 1 Time line of experimental procedure. Protocol starts with HJF diet
at week 0. Thereafter, different treatments across time the 35-week period
are depicted. HJF, human junk food; STZ, streptozotocin; SR, spatial
recognition memory tests; GTT, glucose tolerance tests; Aβ + indicates
time following the end of infusion of Aβ
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incubated with other antibodies using the same procedure
as described above. Protein bands were quantified using
Gene Tools software (SynGene, Cambridge, UK). Total
proteins were normalised to β-Actin and phosphorylated
proteins to corresponding total protein. These were then
normalised to the controls per gel as percent change. The
relative changes in expression and phosphorylation of pro-
teins were analysed statistically with Student’s t test deter-
mined whether changes were significantly different from
controls, and t test and/or ANOVA to determine group
differences. The control group comprised a pool of naïve
controls and those killed at either week 21 or 34 as prelim-
inary analyses showed there were no significant differ-
ences between these groups.
Brain Tissue Preparation for Immunohistochemical
Analyses of Aβ
Rats were deeply anaesthetised with pentobarbital
(200 mg/kg, i.p.) and perfused transcardially with a solu-
tion containing 4% paraformaldehyde in 0.1 m phosphate
buffer and brains were postfixed overnight in the same
perfusion solution at 4 °C, immersed for 6 d in phosphate
buffer containing 30% sucrose, and frozen in chilled 2-
methylbutane (− 30 °C). Free-floating serial sections were
pretreated with hydrogen peroxide to neutralise endoge-
nous peroxidase activity. Non-specific binding sites were
blocked with 4% normal goat serum. Sections were then
incubated with the OC anti-Aβ polyclonal antibody
(Euromedex, 1:3000) at 4 °C overnight. OC antibody rec-
ognises amyloid fibrillary deposits but also a subset of
Aβ oligomers [44]. Incubation using secondary biotinyl-
ated goat anti-rabbit antibody (Vectorlabs) was then per-
formed at room temperature for 2 h. The secondary anti-
body was finally detected by the peroxidase-avidin-biotin
technique (ABC Elite Kit, Vector labs) with 3,3′-diamino-
benzidine (DAB, Sigma-Aldrich) as chromogen. Sections
were then collected on Superfrost glass slides, air-dried
and finally dehydrated and cleared in grading alcohols
and xylene and mounted in Eurokitt mounting medium.
Sections were scanned with a NanoZoomer 2.0-RS slide
scanner (Hamamatsu Photonics, pixel size 0.25 μm2) to
generate virtual slides. Following Aβ immunohistochem-
istry and scanner digitization, 3 regions of interest (dorsal
hippocampus, prefrontal cortex, corpus callosum) were
manually outlined on microphotographs (3 sections/re-
gion/rat). The optical density (OD) of each brain area
was assessed using the MCID Elite image analysis soft-
ware (Linton, Cambridge, UK). OD was normalised rela-
tive to the staining of the corpus callosum, which served
as baseline value to obtain relative optical densities
(ROD) of the prefrontal and hippocampal regions.
Statistical analyses were conducted using the non-
parametric Kruskall-Wallis and Mann Whitney tests.
Results
We conducted experiments over 35 weeks to determine
whether coupling STZ injections with HJF would induce clas-
sic T2D characteristics and whether infusion of Aβ42 would
exacerbate a functional readout (hippocampal-dependent
memory) and basal regulation of protein in and associated
with IR/PI3K/Akt signalling in CA1 of the hippocampus
(see timeline of treatments depicted in Fig. 1).
T2D Characteristics: Food Intake and Weight Gain
As the aim of our experiment was to mimic human food con-
sumption rather than an extensive study on the effect of dif-
ferent nutritional categories of food stuffs, we made cursory
analyses of the food consumption over a 6-week period in the
middle of the experiment in a subgroup of rats fed laboratory
diet (control and STZ; n = 13) and cafeteria diet (HJF and
STZ-HJF; n = 11). Rats fed HJF, consumed nearly twice the
amount of calories per week (853 kcal) compared with those
fed Laboratory Diet (LD, 488 kcal; p < 0.01 Wilcoxon test;
Fig. 2a). In terms of the major nutritional food groups, rats fed
HJF consumed about the same amount of carbohydrates as
those fed LD (p > 0.05; Wilcoxon test); less overall protein
content (p < 0.01; Wilcoxon test) but more lipids (p < 0.01;
Wilcoxon test, Fig. 2b). However, the amount of sugar
contained in the HJF was approximately 49.4% whereas in
LD it was 3.7%, and protein content in HJF was mainly de-
rived from animal proteins whereas it was at least 66% vege-
table proteins in LD. The other major differences in nutritional
composition are shown in Fig. 2d.
Weight was measured on a weekly basis; at the start of
experiment, all rats had the same weight (F < 1), but across
time, those fed HJF (HJF and STZ-HJF) gained significantly
more weight than those groups fed LD (controls and STZ). By
the end of the experiment, rats fed HJF gained approximately
25% more weight than those on the control diet (F(3,96) =
12.78; p < 0.0001; see Fig. 2c).
T2D Characteristics: Plasma Glucose Levels
We conducted 4 glucose tolerance tests (GTT) at different
time points throughout the experimental period (see timeline;
Fig. 3a) and usedANOVA and Tukey post hoc analyses. Basal
glucose levels in the first (week 12: F(3,82) = 2.79; p < 0.05)
and second test (week 19: (F(2,57) = 5.34; P < 0.01) were
modestly but significantly increased only with STZ-HJF treat-
ment compared with controls. By the third (week 25:
F(3,31) = 9.71; p < 0.001) and fourth (week 33: F(3,31) =
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8.84; p < 0.001) tests, basal glucose was greatly elevated in
STZ-HJF treated rats compared with controls but also with
STZ and HJF treatment (all post hoc values p < 0.05; Fig. 3b).
At the same time points, we also assessed plasma glucose
levels following a glucose challenge using a standard glucose
tolerance test (GTT) and analysed the area under the curve
(AUC). In all 4 tests, STZ-HJF treated rats showed a signifi-
cantly greater AUC value compared with all other groups
(week 12: F(3,81) = 21.63; p < 0.001; week 19: F(2,57) =
12.17; p < 0.001; week 25: F(3,29) = 7.33; p < 0.001; week
33: F(3,32) = 12.42; p < 0.001; all post hoc analyses; p < 0.05;
Fig. 3c).
Repeated measures ANOVA and post hoc analyses on the
subgroup of STZ-HJF treated rats tested at all time points
showed a significant difference in basal glucose levels
(F(3,18) =1.43; p < 0.01) and AUC (F(3,18) = 6.48; p <
0.01) between the first 2 and the last two tests (post hoc anal-
yses, p < 0.05; Fig 3b, c) and this is reflected in Fig. 3d, e
showing glucose curves per group in mg/dL in the first and
last test. In summary, only STZ-HJF treated rats showed ob-
vious hyperglycemia as they had a consistent increase in basal
fasting plasma glucose and impaired glucose tolerance in re-
sponse to glucose challenge that evolved with time.Moreover,
repeated measures ANOVA and post hoc analyses on the sub-
group of STZ-HJF treated rats tested at all time points (F(3,
18) =1.43; p < 0.01) showed a significant difference in glucose
levels between the first 2 tests and the last two tests (post hoc,
p < 0.05).
T2D Characteristics: Basal Plasma Insulin Levels
At the end of the experiment, plasma insulin was measured
using ELISA. ANOVA showed very high levels in rats fed
HJF (n = 8) that is a common feature of obesity [19]; with a
slight but non-significant increase in rats in the STZ group
(n = 5) compared with controls (n = 7). In STZ- HJF treated
rats insulin levels at week 21 (n = 5) were hugely increased
above control levels and even that observed in rats in the HJF
group. However, by the end of the experiment (week 35; n =
4), this early increase was dramatically decreased, such that
there was no longer any difference between this group and
controls (F(4,19) = 32.83; p < 0.001; Fig. 4a).
To compare the relationship between glucose and insulin,
we normalised plasma insulin and glucose levels, in the last
test to their corresponding controls (Fig. 4b). In rats in the HJF
group, there was a huge and significant increase in insulin
levels compared with relatively normal levels of glucose (t =
7.89; p < 0.001) suggesting either insulin resistance and/or
hyperinsulinemia. At week 21, STZ-HJF treated rats showed
a similar relationship between glucose and insulin as that
Fig. 2 Food intake and weight gain. a Shows the relative caloric intake in
rats fed LD (n = 13) or HJF (n = 11). b Indicates the consumption ofmajor
food groups, Carb, Prot, and Lipids. cWeight gain in the 4 major groups
Ct and STZ alone (both fed LD), HJF alone and STZ-HJF (both fed HJF).
d Percentage of nutritional components in LD and HJF. STZ,
Strepotozotocin, HJF, human junk food diet; LD, laboratory diet; Carb,
carbohydrates; Prot, protein. ** p < 0.01
Fig. 3 Plasma glucose regulation. aDepicts the time line and numbers of
animals tested in each group. b Shows evolution of fasted basal glucose
levels (0-time point; mg/dL) across the 4 time points. c Shows area under
curve (AUC) of individual response curves to a glucose challenge.
Statistical analyses were conducted on AUC, figures d and e show the
mean group differences of the response curves in first test (d) and the last
test (e) in mg/dL. Data is represented as mean ± SEM; *p > 0.05; **p <
0.01; ***p < 0.001. NB the HJF group alone was not test at GTT2
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observed with HJF, inasmuch as there was relatively no
change in glucose levels and substantially high levels of insu-
lin (t = 18.73; p < 0.001). In contrast, by week 35, STZ- HJF
treated rats showed an increase in glucose with a relative de-
crease in insulin compared with glucose levels (t = 2.36; p <
0.05) and with insulin levels at the earlier time point (t = 5.35;
p < 0.01), with no difference in the ratio of glucose to insulin
(t = 0.69; p > 0.05). As only the STZ-HJF treatment induced
the classic signs of a T2D phenotype, we subsequently fo-
cussed on this group for behavioural experiments. Rats
injected with STZ alone or were fed HJF diet alone did not
undergo memory tested or were subjected to environmental
enrichment.
Memory Deficits Induced by STZ-HJF Treatment
To test whether the STZ-HJF treatment impacted memory, we
tested recognition memory 4 times throughout the experimen-
tal period (see time line; Fig. 5a). In the first test at approxi-
mately week 18, we tested rats using spatial recognition mem-
ory, where the location of one object was changed following a
3-(SR3h) or 24-(SR24h) hour delay, and object recognition,
where one object was replaced with a novel one following a
24-(OR24h) hour delay. We found rats treated with STZ-HJF
showed no deficit comparedwith control in spatial recognition
with a 3-h delay (t = 1.72; p < 0.05). However, with a 24-h
delay, there was a modest but significant deficit compared
with controls (t = 7.3; p < 0.0001); albeit their performance
was significantly greater than chance level (Wilcoxon test:
p < 0.0001 compared with 50%). In addition, there was no
deficit in novel object recognition (OR) at 24 h (t = 1.83;
p < 0.05, Fig. 5b); therefore, we continued only with spatial
recognition with a 24-h delay. Here, we found the same mod-
est deficit in the subsequent tests compared with controls
(week 23; t = 6.82; p < 0.0001; week 27: t = 6.73; p <
0.0001; week 34: t = 6.3 p < 0.0001) but performance was still
significantly above chance (all p < 0.001, Wilcoxon test). In
all 4 SR24h tests, during the sample phase, rats showed equal
exploration of the 3 objects compared with the control group
(all tests, p > 0.05; data not shown), suggesting the STZ-HJF
treatment had no discernible effect on locomotor activity,
stress or the normal tendency for exploring objects.
Together, this suggests that STZ-HJF treatment impaired spa-
tial recognition memory, but this was a modest deficit.
Moreover, the impairment remained remarkably stable across
time (Fig. 5c).
Infusion of Aβ Alone, and in Conjunction with STZ-HJF
Treatment on Spatial Recognition Memory
We tested rats on spatial recognition memory with a 24-h
delay prior to infusion of Aβ to establish a baseline level of
performance, and at 3 time points after (see time line Fig. 6a).
Quite simply, control rats infused with Aβ showed a deficit
16 days following infusion compared with non-infused coun-
terparts (t = 10.92; p < 0.001), but recovered to control levels
by day 44 post infusion (t = 1.68; p > 0.05) and this was main-
tained at 96 days post infusion (t = 1.03; p > 0.05; Fig. 6b).
As expected, 16 days following infusion of Aβ rats with
STZ-HJF treatment showed a deficit in performance as it
dropped to chance level, compared with non-infused STZ-
HJF treated rats (t = 4.57; p < 0.0001) and this deficit was
maintained for the next two tests (44 and 96 days post-Aβ
infusion) compared with non-infused STZ-HJF treated rats
(day 44: t = 5.97; p < 0.001; day 96: STZ-HJF: t = 5.05; p <
0.001; Fig. 6c). These data suggest infusion of soluble Aβ42
alone induced a temporary deficit in performance in a spatial
recognition task; however, on a T2D background, the deficit is
prolonged.
Fig. 4 Plasma insulin regulation. a Plasma insulin levels (ng/ml) at the
end of the experiment in the 4 experimental groups. b Relationship
between glucose (solid bars) at the last test and insulin (hatched bars)
when killed. Data are normalised to respective control levels and are
represented as % change. NB, STZ-HJF group is measured at two time
points. Data are represented as mean ± SEM; ***p < 0.001. Ct (n = 7);
HJF (n = 8); STZ n = 5); STZ-HJF-21 W (n = 5); STZ-HJF-35 W (n = 4)
Fig. 5 Effect of STZ-HJF treatment on different forms of recognition
memory. a Depicts the time line of memory testing and numbers of
animals at each test. b Shows the per cent exploration of the novel loca-
tion at 2 different time intervals and percentage exploration of a novel
object with a 24-h delay. b Shows % exploration of the novel location
with a 24-h delay at different time points throughout the experiment. Data
is represented as mean ± SEM; ***p < 0.001. SR3h, spatial recognition
memory with a 3-h delay; SR24h, spatial recognitionmemory with a 24-h
delay; OR24h, object recognition memory with a 24-h delay
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Beneficial Effect of Environmental Enrichment
on Recognition Memory Performance
We first tested whether EE had a beneficial effect on memory
performance, using 2 delays between sample and test phases
(24 and 72 h) at different time points following EE. We found
enriched rats showed no beneficial effect compared with
home-caged rats when the retention delay was 24 h (31 days
post EE: t = 0.75; p > 0.05; 60 days post EE: t = 0.38, p >
0.05). When the delay was extended to 72 h, enriched rats
maintained the same level of performance as they did with a
24-h delay; however, in home-caged rats, although their per-
formance was significantly greater than chance level
(Wilcoxon test, p < 0.01 at both time points), it was signifi-
cantly poorer compared with enriched rats (t = 2.64; p < 0.05
and t = 2.68; p < 0.05 at both time points). These data suggest
with a 24-h delay, all rats had reached asymptotic level of
performance; however, when increasing the demand on mem-
ory by increasing the retention delay, EE endowed a long
lasting beneficial effect (Fig. 7a).
We used the same protocol to test whether EE could benefit
rats infused with Aβ alone and those receiving STZ-HJF and
STZ-HJF + Aβ treatment (time line, Fig. 7b). The first test
(24-h delay) was after Aβ infusion but prior to EE and served
as a baseline effect for EE. Aβ infusion in both controls (t =
6.71; p < 0.001) and STZ-HJF treatment (t = 3.2; p < 0.05)
induced poorer performance when compared with that of their
non-infused counterparts as we have shown in the previous
experiment (Fig. 7c, d). The first two tests post EE were con-
ducted with a 24-h delay and control rats infused with Aβ
showed equivalent performance compared with non-infused
controls (EE+4 days: t = 1.56; p > 0.05; EE+39 days: t = 0.97;
p > 0.05; Fig. 7c). EE+4 days is within the time window in
which Aβ impairs performance, but EE+39 days is out with
the time window, confirming the recovery is stable (Fig. 6b).
However, when a 72-h delay was imposed in tests outside the
Aβ time window; performance in Aβ-infused rats dropped
17 days post EE, although did not reach statistical significance
compared with controls (t = 2.18; p = 0.07). Performance,
however, recovered to control levels (t = 1.56; p > 0.05) by
the last test (EE+47 days, Fig. 7c). Together, the data suggests
when the retention interval is increased, imposing a greater
demand on memory, the deleterious effect of Aβ is still ob-
served at 17 days post EE, but has recovered by EE+47.
With the first test following EE (EE+4 days), both STZ-
HJF treated rats (t = 9.56.0; p < 0.001; paired t test) and those
infused with Aβ (t = 2.8; p < 0.05) showed improved perfor-
mance compared with that prior to EE; however, despite the
improvement, STZ-HJF-treated rats infused with Aβ had sig-
nificantly poorer performance than non-infused counter parts
(t = 4.21; p < 0.01). By the second test (EE+39 days), the
beneficial effect observed 4 days post EE in both groups had
dropped back to pre-EE levels with no significant difference
Fig. 6 Effect of Aβ alone/in conjunction with STZ-HJF treatment on
spatial recognition memory with a 24-h delay. a Shows the time line of
testing and the number of animals per group. b Histograms represent
percent exploration of the novel location at different time points in con-
trols and rats infused with Aβ alone. c Histograms represent % explora-
tion of the novel location at different time points in STZ-HJF and STZ-
HJF +Aβ treated rats. NB, non-infused groups are the same as those
depicted in Fig. 5. Data is represented as mean ± SEM; ***p < 0.001
Fig. 7 The effect of environmental enrichment (EE) on control and STZ-
HJF treated rats infused with Aβ. a An initial experiment determined the
impact of EE (n = 5) in control rats compared with home-caged (n = 5) at
different times following EE. Time-delay between the sample and test
phase is either 24 or 72 h. b Represents the time line of experimental
testing for the effect of EE on STZ-HJF treated and control rats. c
Memory capacity in control rat infused with Aβ or not; prior to and at
different time points after EE. d Represent STZ-HJF treated rats infused
with Aβ or not at the same time points as control rats. Data is represented
asmean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001. Ct (n = 4); Aβ (n =
5); STZ-HJF (n = 4); STZ-HJF+ Aβ (n = 5)
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between the 2 time points (STZ-HJF: t = 0.15; p > 0.05; STZ-
HJF + Aβ: t = 2.48; p < 0.05; paired t tests). With the first test
with a 72-h delay (EE+17 days), both groups were at chance
level (STZ-HJF: p > 0.05; STZ-HJF + Aβ: p > 0.05;
Wilcoxon test), suggesting the beneficial effect of EE was
short lasting; therefore, these rats underwent no further testing
(Fig. 7d).
Protein Regulation by STZ-HJF Treatment Coupled
with Infusion of Aβ
We found the combined STZ-HJF + Aβ treatment regulated
all protein expression and phosphorylation with the exception
of expression of Akt and NFκB compared with controls at
either week 21 (3 days post infusion of Aβ) or week 35
(17 weeks post infusion of Aβ), and, although phosphoryla-
tion of BAD was increased at 21 weeks, it was not sustained
(Table 1, columns F, G). In terms of the evolution of changes,
we found 4 different patterns of regulation. (1) Those proteins
regulated at 21 weeks and maintained, and in general, these
constituted an increase mainly in expression of mTOR, BAD,
FoxO3 and phosphorylation of mTOR (see p values indicated
by asterisks in Table 1); albeit pmTOR had significantly re-
duced phosphorylation by week 35 compared with week 21
(t = 3.83; p < 0.01). However, comparison of phosphorylation
of mTOR against expression of mTOR respective proteins at
either time point was no different from that of controls
(F(1,3) = 0.24; p > 0.05; Table 1). (2) A second pattern was a
change in levels at 21weeks that was exacerbated by 35weeks
that included a decrease in expression of GluT-1 (t = 5.87; p <
0.01). (3) Thirdly, there was a change in one direction at
21 weeks that was reversed above control levels including
an early decrease that reversed to increased expression of
Gsk3β (t = 4.49; p < 0.01) and phosphorylation of NFκB
(t = 6.42; p < 0.001) and conversely, the increase in pGsk3β
reversed to a decrease (t = 4.21; p < 0.01). (4) Finally, there
was a late developing increase in the expression of APP, and
decrease in expression of IDE, Beclin-1 and pAkt in the ab-
sence of change at week 21 (Table 1).
Protein Regulation by STZ-HJF Treatment Alone
Only a subset of proteins were regulated by STZ-HJF treat-
ment alone compared with those regulated by the group in-
fused with Aβ (Table 1, columns B, C); and in general, most
of these proteins were regulated in the similar manner to the
STZ-HJF +Aβ group. These included an increase in expres-
sion of BAD and FoxO3 at week 21 that was maintained up to
35 weeks. Similarly, regulation of pNFκB went from an early
decrease to a late increase (t = 8.17; p < 0.001; Fig. 8a,c). The
only difference was in regulated expression of mTOR, which
although was increased at week 35, as with the STZ-HJF +
Aβ group, it was not increased at the early time point
(Table 1). Importantly, STZ treatment alone had negligible
effects on protein regulation; it induced an increase in expres-
sion of mTOR that was significantly elevated compared with
control rats (t = 3.05; p < 0.01) and, although less than that
induced by the combined treatment, it was not a significant
difference (t = 0.92; p > 0.05). HJF alone also induced a sim-
ilar increase in mTOR (t = 2.75; p < 0.05) FoxO3 (t = 4.18;
p < 0.001) that was equivalent to the levels induced by STZ-
HJF and STZ-HJF + Aβ treatments (p values > 0.05). This
suggests, in particular, HJF might be responsible for the
changes in some of these proteins induced by STZ-HJF treat-
ment (Online Resource 3).
Protein Regulation by Aβ Alone
Aswith STZ-HJF treatment, Aβ alone induced only a subset
of changes in protein levels compared with STZ-HJF treated
rats infused with Aβ. Of the proteins regulated by Aβ, the
majority of them showed early regulation at 21 weeks
(3 days post Aβ infusion) but were not sustained that would
argue for the peptide being eliminated. These include an
early decrease in expression of Gsk3β and GluT-1 and an
increase in expression of BAD. This is in keeping with the
early deficit in memory performance that recovers with
time. Expression of FoxO3 was increased at 21 weeks and
maintained, but similarly to STZ-HJF treatment. Finally, in
a similar manner to STZ-HJF treatment, there was a delay in
the increase in expression of mTOR at week 35 (Table 1
columns D, E).
This synthetic form of Aβ42 induces small round olig-
omers with diameters of 3 to 30 nm analysed by transmis-
sion electron microscopy (TEM; Fig. 9a) and remains rel-
atively stable for a long time [41]. We also found no evi-
dence of fibrillar or classic aggregated Aβ in the dorsal
hippocampus at the end of infusion of the peptide com-
pared with control rats (U = 4; p > 0.05, Mann Whitney)
or between control (n = 4) and STZ-HJF treated rats (n = 3;
H = 4.79; p > 0.05, Kruskall-Wallis) at the end of the ex-
periment (Fig. 9b). At week 35, OC immunostaining
showed weak but significant diffuse staining in all groups
(Fig. 9c) that was absent from control negative sections
(primary antibody omission, data not shown) that
contrasted sharply with control positive sections (tissue
from an old APPxPS1 transgenic mouse harbouring severe
brain amyloidosis, data not shown). OC immuno staining
therefore suggests that Aβ was in a prefibrillar form [44].
Although we did not biochemically analyse Aβ42 and
therefore cannot whether infusion of the peptide was still
present in the brain by the end of the experiment, the data
suggest that at least it was non longer at an effective level
to induce a deficit in memory and dysregulation of many
proteins.
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Impact of Environmental Enrichment on Expression
and/or Phosphorylation of Proteins
Protein regulation was tested 9–10 weeks following the end of
EE at week 35, as in all other experiments.We first asked what
the impact EE alone was and found only Glu-T1 expression
was increased in control enriched animals (t = 8.32; p <
0.001), but also in all other groups compared with non
enriched counterparts (Table 1, column H, Fig. 10a); however,
there was no significant difference between groups (F(1,3) =
0.29; p > 0.05). We then asked whether EE could reverse
changes induced by STZ-HJF treatment coupled with infusion
of Aβ. Specific to STZ-HJF + Aβ treated rats, EE rectified the
decrease in pAkt (t = 3.34; p < 0.05) and the increase in
pmTOR (t = 6.56; p < 0.001) to control levels and induced
an increase in pGsk3β compared with controls (t = 2.84; p <
0.01) and non-enriched counterparts (t = 4.93; p < 0.01,
Fig. 10b). However, as both increase in expression of mTOR
and Gsk3βwere not modified by EE (see Fig. 11), the relative
change in phosphorylation of these proteins suggests Akt has
a negligible effect. EE also modified phosphorylation of
pNFκB and expression of IDE and BAD induced by STZ-
HJF treatment whether infused with Aβ or not (Table 1,
Fig. 10c). It reversed the increase in pNFκB induced by
STZ-HJF alone (t = 3.22; p < 0.05) and STZ-HJF + Aβ (t =
4.03; p < 0.01) to control levels.
Although STZ-HJF treatment alone did not modify expres-
sion of IDE, EE induced a significant increase compared with
controls (t = 7.23; p < 0.001) and non-enriched counterparts
(t = 6.05; p < 0.001) and increased expression of IDE in STZ-
HJF + Aβ treated rats compared with non-enriched counter-
parts (t = 4.73; p < 0.01) that only reach control levels
(Table 1, columns G, K). Similarly, the increase in expression
of BAD was significantly decreased in both groups compared
with non-enriched counterparts (STZ-HJF: t = 8.1; p < 0.001;
STZ-HJF +Aβ: t = 8.06; p < 0.001); however, the decrease in
STZ-HJF +Aβ treated rats was still elevated compared with
controls (t = 4.46; p < 0.001; Fig. 10c), suggesting that in both
enriched and non-enriched rats, phosphorylation of BAD in
both groups was still in an active state. Finally, STZ-HJF +
Fig. 8 Regulation of proteins specific to STZ-HJF + Aβ treatment.
Group means±SEM are represented for Ct + Aβ (n = 5); STZ-HJF (n =
5); STZ-HJF +Aβ (n = 4) at W21 and Ct + Aβ (n = 5); STZ-HJF (n = 5);
STZ-HJF +Aβ (n = 5). a Represents changes in basal proteins specific to
STZ-HJF +Aβ treatment that develop by the late time point (35 weeks);
b represents changes in basal proteins specific to STZ-HJF +Aβ treat-
ment that evolve across time; c sample western blots represent the group
mean of each protein, including the control group (n = 16). NB as statis-
tical analyses was based on the % change from control; the representative
band is the same in Figs. 11 and 12. Asterisks above histograms represent
significant change from controls, and those above the bars represent sig-
nificant differences between groups; *, p < 0.05; **, p < 0.01; ***, p <
0.001. # indicates difference between each group at the two different time
points, #, p < 0.05; ##, p < 0.01; ###, p < 0.001
Fig. 9 Regulation of proteins induced by treatments independently.
Group means±SEM are described in the legend of Fig. 8. a Protein
regulation we attribute to STZ-HJF treatment alone. b Protein changes
in which infusion of Aβ at least contributes to changes induced by STZ-
HJF +Aβ. c Increase in Fox03 is regulated by all treatments indepen-
dently. d Sample western blots represent the group mean of each protein,
including the control group (n = 16). Asterisks indicate significant chang-
es from control rats, *, p < 0.05; **, p < 0.01; ***, p < 0.001. # indicates
differences between each group at the two different time points, #, p <
0.05; ##, p < 0.01; ###, p < 0.001
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Aβ regulation of Gsk3β, APP and Beclin-1, and regulation of
specific to STZ-HJF rats infused with Aβ and regulation of
FoxO3 and mTOR induced by all treatments were immune to
EE (Table 1, columns J, K; Fig. 11).
Discussion
The aim of these experiments was to determine whether a T2D
phenotype could exacerbate deregulation of proteins in CA1
in or associated with IR/PI3K/Akt signalling induced by infu-
sion of soluble Aβ alone. Our data show that when a soluble
form of Aβ42 is infused in rats with a T2D profile, it induces
long-lasting impairment in hippocampal-dependent memory
and alteration of proteins in or associated with insulin/PI3K-
Akt signalling in CA1. Treatment to induce T2D and infusion
of Aβ alone had differential impact on memory processing
and regulation of proteins. Finally, a mild form of environ-
mental enrichment had a temporary beneficial effect on mem-
ory and could reverse some but not all changes in proteins.
Although a number of the results we found find are subtle, it
likely reflects changes induced in the early stages of AD and
suggests they present a good case for some of the mechanisms
by which T2D could pose a risk factor for AD.
Development of a T2D Phenotype
To our knowledge, this is the first time subdiabetogenic doses
of STZ have been couple with human junk food to induce a
characteristics of T2D. Mostly, STZ injections are coupled
with calibrated high fat and/or high calorific diets as together
they induce inflammation induced destruction of β pancreatic
cells, impaired insulin secretion and stable hyperglycemia
[37] and has been reported in numerous studies models [38].
Although consumption of HJF compared with calibrated obe-
sity inducing diets inheritantly adds more variance into the
results, what is lacking in calibrated diets is the presence of
artificial additives such as preservatives, emulifiers, and
colourants. Alone, food additives are capable of altering the
Fig. 10 Aβ42 peptide. a TEM image of Aβ oligomers following 1 week
of incubation in aCSF at 37 °C. Small, round oligomers could be detected
with diameter in the range of 3 to 30 nm. Scale bar 200 nm. b Relative
optical density (mean ± SEM) of Aβ immunoreactivity in control (n = 4)
and Aβ (n = 3) infused rats 7 days after infusion of Aβ and at 35 weeks
post infusion in control (n = 4) Aβ-infused rats (n = 3), STZ-HJF treat-
ment (n = 3) and STZ-HJF +Aβ treatment (n = 3). c Microphotographs
of the dorsal hippocampus show diffuse staining after incubationwith OC
antibody. Scale bar 2 mm
Fig. 11 Beneficial effect of environmental enrichment (EE) on proteins
regulated by different treatments. Group means±SEM are represented for
enriched groups: Ct-EE (n = 4); Ct + Aβ-EE (n = 4); STZ-HJF-EE (n =
5); STZ-HJF +Aβ-EE (n = 5) at W21 and Ct + Aβ (n = 5); STZ-HJF
(n = 5); STZ-HJF + Aβ (n = 5). Histograms for corresponding non
enriched groups are those represented in Figs. 8 and 9. a Shows changes
specific to EE as it induced change in control rats. However, it also
induced changes in all other groups. b Indicates changes induced by EE
in STZ-HJF + Aβ treated rats. c Indicates change in both STZ-HFJ
groups whether infused with Aβ or not. d Sample western blots (NB,
representative blots for controls and non enriched groups are the same as
those in Figs. 8 and 9). Asterisks indicate significant differences from
control rats; *, p < 0.05; **, p < 0.01; ***, p > 0.001. § indicates where
EE induced a significant difference compared with non-EE counter parts
in each group; §, p < 0.05; §§, p < 0.01, §§§, p < 0.001
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composition of microbiota and the gut brain axis [45].
Although rats fed HJF diet could not be considered obese
compared with certain genetic models [46, 47], their weight
is in the same range of a number of studies using cafeteria diet
[48]. Moreover, it has been suggested that weight gain be-
tween 10 and 25% is an indicator of obesity [49, 50].
Coupling the HJF with STZ injections induced classic
signs of a T2D phenotype that evolved with time where at
the earlier stage rats displayed signs of hyperinsulinemia or
insulin resistance but by the later stage they displayed hyper-
glycemia and much lower insulin levels that could suggest the
start of β-pancreatic cell failure and a more advanced stage of
T2D [51, 52] when certain patients require injections of
insulin.
Memory Deficits Induced by Different Treatments
Apart from the pathology, memory deficits are what clas-
sically define AD and an increasing number of studies are
showing that T2D is also associated with memory deficits
[16]. In our experiments, we found that the T2D pheno-
type and infusion of Aβ alone induced different profiles
of impairment, where T2D induced a mild but stable im-
pairment and Aβ induced a more severe but temporary
deficit. Together, however, the T2D phenotype prolonged
the deficits induced by Aβ alone. To date, most experi-
mental studies investigating memory impairment have
demonstrated deficits in transgenic mice or with infusion
of different species of Aβ; however, they have not repeat-
edly tested memory over a protracted period of time. Our
results do find support in one study showing injections of
oligomeric Aβ42 induced a temporary deficit in spatial
memory that recovered [53] and another that showed in-
jections of Aβ42 in rats made diabetic with STZ and high
fat diet induced a more severe deficit in spatial memory
compared with the treatments alone [54]. Importantly, a
number of studies have shown high fat and/or high su-
crose diet fed to AD transgenic mice accelerate cognitive
deficits [55–61]; however, some show the deficits are in-
dependent of amyloid pathology [23, 52, 57]. This sug-
gests that the dementia associated with AD is more likely
triggered by multiple dysfunctional mechanisms indepen-
dent of Aβ or associated with preaggregated species that
may occur in parallel or at different stages of the disease
as suggested by Herrup and colleagues [62, 63].
Environmental enrichment (EE) had a beneficial effect in
all conditions; however, in control rats, this is dependent on
demand onmemory, and in those infused with Aβ, it unmasks
a residual deficit at this longer retention delay. EE had a ben-
eficial effect on performance in STZ-HJF treated rats either
with or without infusion of Aβ; however, this was short last-
ing in both groups. Although EE has been shown to benefit
memory in models of AD [40], its effects are subject to
variables such as age at which animals are exposed, duration
and strength of enrichment [64], and it is possible that extend-
ing the duration of EE or coupling it with exercise [65] may
have a greater impact on STZ-HJF treatment with or without
Aβ.
Regulation of the Akt Signalling Pathway
and Associated Proteins in CA1 by Different
Treatments
We examined basal expression and phosphorylation of pro-
teins in CA1 as it is highly vulnerable to dysfunctions in early
or prodromal stages [66–68]. All proteins were normalised to
control/gel as % change. These values per group were then
subsequently used for statistical analyses (see Table 1) and
analysis of their regulation was conducted on two different
levels. Firstly, we assessed whether protein regulation was
specific to the combined STZ-HJF + Aβ treatment and wheth-
er this evolved with time; and secondly, how regulation of
these proteins might contribute to dysfunction observed in
AD vis a vis the existing literature. Most of the proteins we
examined were altered by STZ-HJF + Aβ treatment, only ex-
pression of Akt, BAD and NFκB was not affected by any of
the treatments. In general, at the late stage, STZ-HJF + Aβ
induced increase in expression of total proteins and a decrease
in the phosphorylated form. However, with Gsk3β, pGsk3β
and pNFκB, the change evoked at the early timepoint was
reversed with time and this may reflect time dependent bi-
phasic [69].
At the most clear-cut level, we considered the late de-
crease in phosphorylation of Akt and expression of IDE,
Beclin-1 and the increased expression of APP were spe-
cific to STZ-HJF treatment in conjunction with infusion
of Aβ, as these proteins are not regulated at the early time
point of 21 weeks, nor are they regulated by Aβ or STZ-
HJF treatment alone at week 35 (Fig. 8a). We also con-
sidered the change in expression of mTOR and phosphor-
ylation of mTOR and Gsk3β that was triggered at the
early time point to be specific to the group in the absence
of change induced by the treatments alone (Fig. 8b).
Finally, the decrease in expression of GluT-1 was specific
to this group, even though there was a similar decrease
induced by Aβ alone at the early time point it was not
sustained.
However, some proteins regulated by STZ-HJF + Aβ treat-
ment were regulated in a similar manner by the treatments
independently at either or both time points. This suggests the
independent treatments may be the driving force behind that
observed in the combined STZ-HJF + Aβ treatment, or that it
may have a contributory effect. For example, the change in
expression of BAD, and phosphorylation of NFκB observed
with STZ-HJF + Aβ treatment, we attribute to the STZ-HJF
treatment alone as the changes are identical with both groups
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with STZ-HJF + Aβ treatment was also induce in a similar
manner by infusion of Aβ alone at the early time point but
was not sustained by the end of the experiment. Finally, the
increase in expression of FoxO3, at both time points, and
mTOR at the end of the experiment were induced by all 3
treatments independently and also by HJF alone, suggesting
these proteins are highly susceptible to different effects that
could be occurring simultaneously but in an independent
manner.
The beneficial effect of EE in general impacted phosphor-
ylation of proteins such as Akt, Gsk3β, mTOR and expression
of proteins associated with insulin (IDE) regulation and glu-
cose transport, important energy sources [70]. However, re-
versal of these effects by EE was not sufficient to maintain
improvement in memory. Moreover, we might speculated that
the lack of effect on mTOR, BAD and FoxO3 regulation may
suggest they are resistant to EE as they can be mediated in
parallel by different treatments independently.
Regulation of Proteins Induced by STZ-HJF + Aβ
Treatment in Association with Dysfunction in AD
Our principle results show that STZ-HJF + Aβ treatment de-
creased phosphorylation of Akt at the late time point and was
specific to this group. Regulation of Akt impacts downstream
target proteins that are associated with hubs of protein inter-
actions that mediate different functions disrupted in AD. The
two most documented axes of regulation studied in AD are
Akt-Gsk3β regulation as this has been implicated for the most
part in tau phosphorylation and an increase in Aβ production
[71] and Akt-mTOR that acts in concert with Akt-independent
proteins to regulate autophagy [72], tau phosphorylation [73]
and vasodilation and cerebral blood flow [10].
The increase in expression of Gsk3β was accompanied
by a decrease in phosphorylation of the protein by Akt.
Under normal conditions, Gsk3β is constitutively active
and phosphorylation by Akt inhibits its activity. Our data
therefore suggest that Gsk3β is in an active state. This is
in agreement with some studies showing an increase in
expression in the brains [24, 25] of AD patients and ex-
perimental studies [74], but not others [26, 75]. More
specifically, our results agree with a single study showing
more severe deregulation of Akt signalling in patients
with AD and T2D than those with AD or T2D alone
[76]. Over expression of GSK3β can hyperphosphorylate
Tau [77] and mediate amyloidogenic processing of APP
[78]. Although we did not measure tau or Aβ, we found
increased expression of APP, which could indirectly sup-
port aberrant processing of APP potentially mediated via
GSK3β. Furthermore, we found a decrease in IDE expres-
sion, a zinc metalloprotease involved in eliminating Aβ
that has been observed in AD patients [79], AD transgenic
mice [80] and transgenic mice fed high fat diet [58]. Our
data therefore support the hypothesis suggesting that over
activity of GSK3β can account for memory deficits, tau
hyperphosphorylation and increased production of Aβ
[81].
STZ-HJF + Aβ treatment also increased expression of
mTOR and pmTOR compared with control rats, but phos-
phorylation was not induced directly by Akt at this spe-
cific site relative to expression of the protein. We also
found the increase in expression of mTOR was regulated
by all treatments, including STZ and HJF alone suggest-
ing it is responsive to numerous signals that could include
nutrient sensing, amino acids and stress signals [82]. Our
results are in agreement with studies in AD showing an
increase in both protein and gene expression [54, 83], and
studies have shown reducing mTOR improves cognition,
reduces Aβ and pTau and improves insulin signalling in
an AD transgenic mouse [84, 85]. However, other studies
have shown an increase in pmTOR at the same Akt site in
the absence of change in expression levels in human AD
brains and tissue [26, 75].
Regulation of mTOR is highly complex; it comprises 2
multiprotein complexes that have different phosphorylation
sites [82] and could potentially undergo differential regulation
at different stages during AD to impact different functions
[86]. We cannot rule out the possibility that either the increase
in pmTOR compared with controls is sufficient to exert an
abnormal level of activation, that it is differentially regulated
by the mTOR complexes [21], or other proteins such as S6K1
that phosphorylate this site that is susceptible to regulation by
rapamycin and phorbol esters in an Akt-independent manner
[87].
In conjunction with the increase in mTOR we also ob-
served a significant decrease in expression levels of
Beclin-1 specific to the STZ-HJF + Aβ group. Beclin-1 is
a key activator of autophagy and works in concert with
inhibition of mTOR to eliminate malformed proteins. A
number of studies have shown autophagy is dysfunctional
and expression of Beclin-1 is reduced in AD and T2D/
obesity [13, 88–90], and overexpression of Beclin-1 pro-
tects against Aβ and increases in APP [72]. Thus, our
results agree with those suggesting autophagic processes
are disrupted in AD.
We also examined proteins regulated by Akt that are
associated with inflammation (phosphorylation of NFκB)
and apoptosis (BAD and FoxO3), common dysfunctional
features in both AD [91–96]. In the absence of change in
expression of the protein, we found hyperphosphorylation
of NFκB at the late time point induced by STZ-HJF treat-
ment regardless of whether rats were infused or not with
Aβ, suggesting STZ-HJF treatment is responsible for the
inflammatory response, which is not surprising as T2D is
known to induce chronic low-grade inflammation, at least
in the periphery [97, 98].
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The increase in expression of both BAD and FoxO3 was
regulated by all treatments, but in a different manner, where
we attributed the increase in BAD to the T2D treatment and
the increase in FoxO3 to both HJF alone and Aβ alone. Under
normal conditions, phosphorylation of BAD and FoxO3 by
Akt prevents activation of cell death mechanisms.
Phosphorylation of BAD prevents it associating with
proapoptotic proteins [98], whereas phosphorylation of
FoxO3 sequesters it to the cytoplasm where it is maintained
in an inactive state [see 99, 100]. The lack of a change in
phosphorylation of BAD relative to the increased expression
of the total protein suggests it is not phosphorylated by Akt
and can be in an active state and potentially promote
apoptosis.
The expression of total FoxO3 protein was also increased;
however, we did not measure phosphorylation of the protein.
Our result, however, is in keeping with other studies that show
(a) an increase in FOXO3a mRNA in Alzheimer brains [101];
(b) inactivation of FoxO3a in the Tg2576mouse model of AD
attenuates AD neuropathology, whereas expression of consti-
tutively active FoxO3a causally promotes amyloid processing
[102], and (c) mice fed high fat diet induced a decrease in
pAkt and an increase in FoxO3a in the nuclear compartment
of neurons [103, 104].
Finally, we found a decrease in Glu-T1 in STZ-HJF +
Aβ treated rats at the early time point that was exacerbat-
ed by the end of the experiment. We also found a decrease
at the early time point induced by infusion of Aβ alone
that was not long lasting, suggesting it may have a con-
tributory effect to that observed with the combined STZ-
HJF + Aβ treatment. Glu-T1 is the principle transporter of
glucose across the BBB and reduction of uptake contrib-
utes to hypoglycaemia [105], a common feature of both
AD and T2D [106]. However, it also maintains the cere-
bral architecture and disruption of its function can results
in decreased blood flow and hypoperfusion as observed in
AD patients and rodent models [107, 108]. Some evi-
dence has shown that Aβ can impair the cerebral vascu-
lature [109], suggesting that dysfunction in the BBB may
be both a cause and a consequence of AD [9] (Fig. 12).
In conclusion, we found regulation of proteins associat-
ed with the promotion of amyloid and tau dysregulation
and deregulation of functions that may be dependent or
independent of early Aβ pathology. As our aim in this first
step was to identify mechanisms associated with these dys-
functions in our model, we can only speculate how aber-
rantly regulated proteins we observe interact to induce dys-
functions based on the existing evidence (described in
Fig. 13) and will require further experimentation.
Nonetheless, our results show a number of important find-
ings. (1) Coupling HJF with STZ has not yet been reported
and this model shows classic signs of T2D and more close-
ly resembles the human condition. (2) The T2D phenotype
and infusion of Aβ alone induce different profiles of mem-
ory impairment, but together, suggests the temporary def-
icit induced by Aβ is prolonged on a T2D background,
reinforcing T2D as a risk factor for AD at least in terms
of a functional readout. (3) Regulation of proteins by dif-
ferent treatment is complex but suggest (a) the most robust
deficits were observed with the combined T2D treatment
with infusion of Aβ, suggesting for the majority of pro-
teins we examined neither the T2D profile nor infusion of
Aβ was sufficient alone to induce these changes. (b) The
majority of changes in protein regulation were an increase
in expression of the total protein with a lack or decrease in
regulation by Akt. As Akt essentially puts a brake on acti-
vation of these proteins, it suggests that they are in an
abnormally active state. (c) Certain proteins, notably ex-
pression of mTOR, BAD and FoxO3, are reactive to inde-
pendent treatments and are resistant to beneficial effects of
EE, suggesting they may be associated with key functions
important in the early stages of AD that are promoted by
T2D.
In total, our results support the growing hypotheses
that suggest dysfunctional mechanisms implicated in me-
diating dementia in AD, are triggered by multiple ‘hits’
on functions essential for the support and maintenance of
the neuronal milieu. They can be induced by amyloid
Fig. 12 Protein changes induced by different treatments that are resistant
to environmental enrichment. Group means±SEM are described in the
legend of Fig. 11. a Those specific to STZ-HJF + Aβ treatment. b
Proteins regulated independently or in combination of different
treatments. c Sample western blots (see explanation of bands from
control and non enriched groups in Fig. 11 legend). Asterisks indicate
significant differences from control rats; *, p < 0.05; **, p < 0.01; ***,
p > 0.001. Data is represented as mean ± SEM. Week 35: Ct + Aβ
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dependent and independent mechanisms that would in
turn depend on the dysfunctional mechanisms associated
with different risk factors coupled with an age-dependent
increase in soluble amyloid peptides.
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Fig. 13 Schema represents how the changes in proteins we observe may
be incorporated in to known dysfunction associated with AD. Akt is a
master regulator of a number of downstream proteins that themselves
interact with hubs of protein complexes to elicit regulation of different
functions. In general phosphorylation of these proteins byAkt is to inhibit
their activity or to prevent their translocation to the nucleus. (1) In keeping
with the decrease in phosphorylation of Akt is a decrease or lack of
phosphorylation of Gsk3β, BAD and mTOR in relation to the increase
in expression of the proteins. The lack of regulation of Gsk3β, can lead to
accumulation of the constitutively active form of the protein. This has
been shown to hyperphosphorylate Tau [73], but can also promote
amyloidogenic process by promoting the liberation of Aβ from APP
[77, 78]. More recently it has been shown Gsk3β can phosphorylate
NFκB that leads to its translocation to the nucleus to activate genes asso-
ciated with apoptosis and inflammation, but also transcribes BACE-1
[110]. (2) Increase in expression of APP proteins and decrease in expres-
sion of IDE suggests accumulation of AβO’s that can bind to TNFα [111]
and can interact with ROS [112] that in parallel can lead to translocation
of NFκB also. (3) Phosphorylation of the BAD and FoxO’s tether them in
the cytoplasm, preventing them activating proapototic genes. The in-
crease in expression of the 2 proteins suggests accumulation and at least
with BAD it is not regulated by Akt, further suggesting they are in an
active form. (4) Although expression of mTOR was increased, it was not
phosphorylated by Akt. However, mTOR comprises 2 multiprotein
complexes that can be phosphorylated by numerous imputs and contrib-
utes to numerous functions. Most relevant to AD and T2D, is that it is a
biosensor of the nutritional/energy status and when activated it promotes
protein translation and when inhibited it permits autophagic recycling or
proteins. It is regulated in concert with Beclin that promotes autophagy
and this is known to be dysfunctional in AD. AMPK is also an important
sensor of nutrients and in non pathological conditions of low nutrient
availability; it inhibits mTOR and activates Beclin-1. As the decrease in
Glu-T1 would suggest a reduced level of nutrients, it should normally
suggest AMPK activation of autophagy possibly via mTOR and Beclin-1
might be triggered. However AMPK levels are reduced in ageing and AD
[113, 114], and as mTOR expression is increased and Beclin-1 decreased,
it would suggest both AMPK and autophagy [115] are dysfunctional. The
consequence of thismay be an increase inmalformed protein synthesis by
mTOR and lack of clearance of these proteins and potentially Aβ species
by autophagy. Recent evidence has also shown that aberrantly increased
mTOR can induce vasoconstriction in neuronal vasculature and cerebral
blood flow, that may contribute to reduced transport of glucose across the
blood brain barrier (BBB), to perpetuate dysfunctional signalling of
energy/nutrients necessary for normal neuronal functioning. Arrows in-
dicate protein changes we find (red) and those previously reported in the
literature (black). Solid lines represent reported relationship between pro-
tein interaction and dysfunction; broken lines represent speculated inter-
action and dysfunction in our experiments
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